MYCN and neuroblastoma: Increased expression levels of RUNX1 are correlated with favorable overall survival and are detected in ganglioneuromas and well-differentiated neuroblastomas, whereas lower levels are present in poorly differentiated, undifferentiated, and non-MYCN amplified neuroblastomas, indicating RUNX1 as a favorable prognostic indicator [51].